Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
50.37
+0.24 (0.48%)
At close: Jul 25, 2025, 4:00 PM
50.49
+0.12 (0.24%)
After-hours: Jul 25, 2025, 4:40 PM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Total Vaccine | 8.30B | Log In | Log In | Log In | Log In | Upgrade |
Total Vaccine Growth | 12.87% | Log In | Log In | Log In | Log In | Upgrade |
Other | 3.21B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Opella Consumer Healthcare | - | Log In | Log In | Log In | Log In | Upgrade |
Opella Consumer Healthcare Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Dupixent | 13.07B | Log In | Log In | Log In | Log In | Upgrade |
Dupixent Growth | 22.10% | Log In | Log In | Log In | Log In | Upgrade |
Total Neurology & Immunology | - | Log In | Log In | Log In | Log In | Upgrade |
Total Neurology & Immunology Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Total Rare Diseases | - | Log In | Log In | Log In | Log In | Upgrade |
Total Rare Diseases Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Total Oncology | - | Log In | Log In | Log In | Log In | Upgrade |
Total Oncology Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Total Rare Blood Disorders | - | Log In | Log In | Log In | Log In | Upgrade |
Total Rare Blood Disorders Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Total Core Assets | - | Log In | Log In | Log In | Log In | Upgrade |
Total Core Assets Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Total Non-Core Assets | - | Log In | Log In | Log In | Log In | Upgrade |
Total Non-Core Assets Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Industrial | - | Log In | Log In | Log In | Log In | Upgrade |
Industrial Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Specialty Care | - | Log In | Log In | Log In | Log In | Upgrade |
Pharma | 32.78B | Log In | Log In | Log In | Log In | Upgrade |
Other | 3.21B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | 3.21B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | -2.47B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Pharmaceutical Operating Income | - | Log In | Log In | Log In | Log In | Upgrade |
Pharmaceutical Operating Income Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Vaccine Operating Income | - | Log In | Log In | Log In | Log In | Upgrade |
Vaccine Operating Income Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Operating Income | - | Log In | Log In | Log In | Log In | Upgrade |
Other Operating Income Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | -2.47B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Consumer Healthcare Operating Income | - | Log In | Log In | Log In | Log In | Upgrade |
Consumer Healthcare Operating Income Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Biopharma Operating Income | 11.29B | Log In | Log In | Log In | Log In | Upgrade |
Biopharma Operating Income Growth | 8.40% | Log In | Log In | Log In | Log In | Upgrade |
Opella Consumer Healthcare (Post-2022 Reporting) Operating Income | - | Log In | Log In | Log In | Log In | Upgrade |
Other (Post-2022 Reporting) Operating Income | 58.00M | Log In | Log In | Log In | Log In | Upgrade |
Other (Post-2022 Reporting) Operating Income Growth | 28.57% | Log In | Log In | Log In | Log In | Upgrade |
Other | -2.47B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | 3.21B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | 3.21B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
United States | 19.99B | Log In | Log In | Log In | Log In | Upgrade |
United States Growth | 14.32% | Log In | Log In | Log In | Log In | Upgrade |
Europe | 9.03B | Log In | Log In | Log In | Log In | Upgrade |
Europe Growth | -5.17% | Log In | Log In | Log In | Log In | Upgrade |
Rest of World | 12.07B | Log In | Log In | Log In | Log In | Upgrade |
Rest of World Growth | -5.78% | Log In | Log In | Log In | Log In | Upgrade |
Other | 3.21B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |